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Autoimmunity has been suggested as one of the pathophysiologic mechanisms that may underlie complex regional pain syndrome
(CRPS). Screening for antinuclear antibodies (ANA) is one of the diagnostic tests, which is usually performed if a person is suspected
to have a systemic autoimmune disease. Antineuronal antibodies are autoantibodies directed against antigens in the central and/or
peripheral nervous system. The aim of this study was to compare the prevalence of these antibodies in CRPS patients with the
normal values of those antibodies in the healthy population. Twenty seven (33%) of the 82 CRPS patients of whom serum was
available showed a positive ANA test. This prevalence is significantly higher than in the general population. Six patients (7.3%)
showed a positive result for typical antineuronal antibodies. This proportion, however, does not deviate from that in the general
population. Our findings suggest that autoantibodies may be associated with the pathophysiology of CRPS, at least in a subset of
patients. Further research is needed into defining this subset and into the role of autoantibodies in the pathogenesis of CRPS.
1. Introduction
Complex regional pain syndrome (CRPS) is a collection of
locally appearing painful conditions following trauma which
chiefly occur distally and exceed in intensity and duration the
expected clinical course of the original trauma.
The pathophysiology is complex and still not com-
pletely understood. It is reasonable to assume that different
mechanisms, for example, inflammation, hypoxia, central
sensitisation, and neuroplasticity, are involved in a complex
network of interactions, resulting in a broad range of signs
and symptoms [1].
The involvement of the immune system in the patho-
physiology of CRPS is appreciated for several reasons. First,
CRPS shows several clinical characteristics of an inflamma-
tory disease, including pain, redness, swelling, and warmth
[2]. Additionally, levels of proinflammatory cytokines are
elevated in blister fluid fromCRPS affected limbs [3, 4]. CRPS
shows a beneficial response to treatment with inhibitors of
inflammation, such as corticosteroids [5].
Complementary is the fact that, similar to many other
chronic inflammatory diseases, CRPS displays a female pre-
dominance [6] and associations with distinct HLA alleles [7–
9]. The incidence of CRPS is higher in patients with chronic
inflammatory disorders, such as asthma [10] and multiple
sclerosis [11].
Autoimmunity has been suggested as one of the under-
lying mechanisms in the pathophysiology of CRPS. There
are several arguments that point in this direction. First, IgA-
antibodies to campylobacter were present in CRPS patients
with short disease duration [12] and an increased seropreva-
lence of Parvovirus B19 in CRPS patients compared to con-
trols has been reported [13, 14]. Both infectious agents have
previously been implicated in the induction of autoimmune
diseases.
Second, immunohistochemistry has revealed the pres-
ence of autoantibodies against nervous system structures in
at least a part of the CRPS patients, included in a study
by Blaes et al. [15]. Another study showed that about 30–
40% of CRPS patients have surface-binding autoantibodies
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against an inducible autonomic nervous system autoantigen
[16]. Third, a subgroup of CRPS patients, that is, those who
developed CRPS with only a minimal preceding trauma,
showed a much stronger immune response against nervous
tissue compared to the whole group [12]. Fourth, animal
studies have demonstrated that the transfer of IgG antibodies
from CRPS patients to mice causes abnormal behaviour and
motor function in thesemice [17]. And finally, treatment with
intravenous immunoglobulin can reduce pain in refractory
CRPS [18].
These results suggest that CRPS is associatedwith autoim-
munity, including an autoantibody-mediated immune pro-
cess, at least in a part of the patients. Interestingly, CRPS is
even considered as prototype of a novel kind of autoimmune
disease [19].
Autoimmune diseases are often associated with an
increased prevalence of positive testing for antinuclear anti-
bodies (ANA). These autoantibodies are reactive with anti-
gens in the nucleoplasm. ANA are probably present in the
circulation of all human beings, but the employed test is
considered positive when titres are elevated significantly
above the normal serum level [20]. Screening for ANA is one
of the diagnostic tests which is usually performed if a person
is suspected to have a systemic autoimmune disease [21].
Antineuronal antibodies, often called “onconeural anti-
bodies” given their paraneoplastic nature in many cases,
are autoantibodies directed against antigens in the central
and/or peripheral nervous system. Antineuronal antibodies
against intracellular antigens in general are not thought to
be pathogenic. On the contrary, the antineuronal antibodies
directed against cell surface antigens are themselves dis-
ease mediating. In contrast to what the name “onconeural”
suggests, antineuronal antibodies are not strictly related to
cancer [22].
The aim of the present study was to further explore
CRPS as a potential autoantibody-associated autoimmune
process. For this purpose, we compared the prevalence of
CRPS patients with a positive test for antinuclear antibodies
and for antineuronal antibodies with the prevalence in the
healthy population.
2. Materials and Methods
This study was approved by the Medical Ethics Committee of
the Erasmus MC Rotterdam (MEC-2012-037).
2.1. Patients. Our Department, a University Center for Pain
Medicine, serves as an expert center for CRPS patients. Both
acute and chronic CRPS patients visit the clinic on their own
initiative or on referral by GP’s or medical specialists. There
is a weekly outpatient clinic especially for CRPS patients, led
by physicians with clinical and research experience in CRPS.
All patients who visited the Center for Pain Medicine
between 2001 and 2007 and fulfilled the Harden-Bruehl
diagnostic criteria for CRPS [23] were invited to participate
in ongoing CRPS studies.
For all patients signs (subjective) and symptoms (objec-
tive), that is, the presence or absence of allodynia, hyperalge-
sia, dystonia, bilateral difference in temperature, difference in
Table 1: Patients’ characteristics.
Characteristics 𝑛 = 82
Woman (𝑛, %) 69 (84.1)
Age in years (mean, SD) 44.2 (12.37)
CRPS duration in months (median, IQR) 11 (36–5)
Cold CRPS (𝑛, %) 44 (53.7)
Warm CRPS (𝑛, %) 31 (37.8)
Unknown (𝑛, %) 7 (8.5)
Upper limb (𝑛, %) 48 (58.5)
Precipitating injury
Trauma (𝑛, %) 53 (64.6)
Operation (𝑛, %) 21 (25.6)
Spontaneous (𝑛, %) 6 (7.3)
colour, difference in sweating, difference in motor range, and
difference in strength, were recorded.
In each patient who participated in a study, venous blood
was drawn. Serum of this blood was stored with permission
to use in future research. For the current study, serum of
82 patients was available. All these patients were classified
as CRPS type 1. The characteristics of the 82 patients are
described in Table 1.
2.2. Laboratory Tests. Venous blood samples were cen-
trifuged immediately after collection at 3000 rpm during 10
minutes and serum was stored at minus 80 degrees Celsius
until use.
Antinuclear antibodies (ANA) were determined accord-
ing to international recommendations [24] with a com-
mercially available test system, according to manufac-
turer’s instructions. Briefly, HEp-2000 cells (Immuno Con-
cepts, Sacramento, CA) were incubated with 1 : 80 diluted
patient serum. After washing, bound autoantibody was
detected using fluorescein (FITC-) conjugated anti-human
IgG (Immuno Concepts) and visualized at 488 nm by fluo-
rescencemicroscopy. ANA results were considered positive if
at least weak positive nuclear staining of HEp-2000 cells was
observed. Borderline results were discarded.
Antineuronal antibodies were determined according to
international guidelines [25] with a commercially available
test system, according to manufacturer’s instructions.
Briefly, primate cerebellar cryosections (IMMCO Diag-
nostics, Buffalo, NY) were incubated with 1 : 400 diluted
patient serum. After washing, bound autoantibody was
detected using fluorescein (FITC-) conjugated anti-human
IgG (IMMCO diagnostics) and visualized at 488 nm by flu-
orescence microscopy. Results were considered positive if at
least weak positive staining of neuronal nuclei (antineuronal
nuclear antibody, ANNA) or Purkinje cells (Purkinje cell
cytoplasm antibody, PCA) was observed. Borderline results
were discarded as well as false positive neuronal nuclear
staining in the presence of a positive ANA.
Since literature reference varies regarding prevalence of
autoantibodies in healthy individuals, mostly due tomethod-
ology, we did not use literature reference for comparison.
Instead, the results of ANA and antineuronal antibody
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obtained in CRPS patients were compared to those we
obtained ourselves in parallel using serum obtained from
randomly selected healthy blood bank donors, using identical
methodology as described above.
2.3. Statistical Analysis. Descriptive statistics were used to
determine the (multiple response) frequencies of the demo-
graphic variables and the outcomeparameters and to describe
measures of central tendency and of variability, dependent
on the shape of their distribution. Testing for normality
of the distributions was performed using the Kolmogorov-
Smirnov test.The difference between the proportion of CRPS
patients with positive (nuclear or neuronal) antibodies and
that in the healthy population was analyzed using the Fisher’s
Exact Test, 2-sided. The same test was applied to evaluate
the difference in proportion of signs and symptoms between
(1) the patients positive and those negative for antinuclear
antibodies and (2) between the patients positive and those
negative for antineuronal antibodies.
Difference in duration of the CRPS between patients with
positive and those with negative antinuclear antibodies was
tested using the Mann-Whitney U test.
Analyses were performed using IBM SPSS Statistics 21.
3. Results
Twenty seven (33%) of the 82 included CRPS patients showed
a positive result for antinuclear antibodies. This proportion
is significantly higher compared to that in the healthy pop-
ulation (𝑛 = 90), in which we observed 4% ANA positivity
(𝑃 < 0.001).
The observed ANA immunofluorescence patterns were
diverse, including homogeneous, speckled and nucleolar
patterns. See Table 2.
No statistically significant difference was found in the
proportion of patients with an ANA positivity between
patients with a cold and those with a warm CRPS, respec-
tively, 34.1% and 32.3% (𝑃 = 0.99). Likewise, no statistically
significant difference in duration of the CRPS was found
between the patients with a positive test for ANA and those
with a negative test (𝑃 = 0.66).
Six (7.3%) of the 82 included CRPS patients showed a
positive result for antineuronal antibodies. This percentage
does not deviate from that in the healthy population (7.5%).
As indicated by the immunofluorescence pattern on the
cerebellum substrate, the majority of reactivity was directed
against neuronal nuclei (ANNA). In addition, reactivity
against Purkinje cell cytoplasm (PCA) was observed. See
Table 3. However, the immunofluorescence pattern in the
healthy population indicated reactivity to basket neurons
and/or neurofilaments, as opposed to the ANNA and PCA
patterns observed in the CRPS patients.
Two patients showed both a positive ANA test (speckled
pattern) and a positive result for antineuronal antibody
(ANNA).
No statistically significant differences in signs or symp-
toms between patients positive and those negative for antinu-
clear antibodies were found.The samewas applied to patients
Table 2: IF pattern of antinuclear antibodies.
Antinuclear antibodies positive 𝑛 = 27
Homogeneous (𝑛, %) 7 (26)
Speckled (𝑛, %) 6 (22)
Nucleolar (𝑛, %) 12 (44)
Homogeneous and nucleolar (𝑛, %) 2 (8)
Table 3: IF pattern of antineuronal antibodies.
Antineuronal antibodies positive 𝑛 = 6
Neuronal nuclei (𝑛, %) 4 (66)
Purkinje cells (𝑛, %) 1 (17)
Neuronal nuclei and Purkinje cells (𝑛, %) 1 (17)
positive and those negative for antineuronal antibodies. For
all proportional differences 0.13 = 𝑃 ≤ 1.
4. Discussion
To gain more insight in the potential role of systemic
and/or organ-specific autoimmunity in the pathophysiology
of CRPS, we studied the prevalence of both antinuclear
antibodies (ANA) and antineuronal antibodies in CRPS
patients.
The reported prevalence of ANA in healthy individuals is
up to 20%ormore.Theprevalence ofANAdepends, however,
on various factors including age, gender, and methodology
[26]. Using our method of ANA testing, the prevalence in
healthy individuals was 4%.
In our CRPS study sample we found a statistically sig-
nificant higher positive ANA prevalence (33%) compared
to that in the healthy population. To correct for a possible
confounder age, since the prevalence of positive testing for
ANA in the general population is higher amongst people
aged above 65 years (up to 30%), we excluded the CRPS
patients aged above 65 years (two patients).The positive ANA
prevalence in CRPS remained significantly higher, 30%.
Diverse ANA patterns were observed in CRPS, including
homogeneous, speckled, and nucleolar patterns. Either pat-
tern can be observed in systemic autoimmune disease but is
not specific to any particular autoimmune disease [27].
The prevalence of antineuronal antibodies in CRPS
patients was 7.3%, showing characteristic ANNA and PCA
patterns [25, 28]. A similar prevalence was found in healthy
subjects, however, showing a clearly different, atypical pat-
tern. The clinical relevance of such patterns is unclear but is
observed more often in subjects without apparent neurolog-
ical disease (Schreurs MWJ, unpublished results). Although
the immunofluorescence pattern in the healthy population,
reactivity to basket neurons and/or neurofilaments, was dif-
ferent as compared to the ANNA and PCA patterns observed
in CRPS patients, this observation may lack meaning due to
the low amount of positive patients identified.
The phenotype does not seem to be different, because the
signs and symptoms did not show any significant differences
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between CRPS patients positive or negative for antinuclear
antibodies, nor for antineuronal antibodies.
Our findings suggest that autoantibodies may be associ-
ated with the pathophysiology of CRPS, at least in a part of
the patients. However, though being increased compared to
the general population, the positive ANAprevalence in CRPS
patients is much lower than in patients with classic systemic
autoimmune disease such as systemic lupus erythematosus
(SLE) that shows a prevalence of 99% [21]. The positive
ANA prevalence in CRPS patients is more in line with the
25% observed in patients with autoimmune diseases such as
rheumatoid arthritis (RA) [21]. Based on these findings, we
may suggest that CRPS is more similar to an autoimmune
disease as RA than to a systemic autoimmune disease as
SLE. This hypothesis is supported by studies that revealed
associations between CRPS and chronic inflammatory dis-
orders, including asthma [10] and multiple sclerosis [11]. To
our knowledge there are no reports of strong associations
between CRPS and autoimmune diseases, although there are
two case reports of cooccurrence of the two disorders in one
patient [29, 30].
The presence of antineuronal antibodies in CRPS patients
has been established in earlier research [15, 16]. In previous
studies, antibodies were directed against a neuroblastoma cell
line. In our current study we used a cerebellum substrate
containing both afferent and efferent nerve pathways, with
sensory and motor function. We chose this substrate because
it resembles peripheral nerve tissue, which seems to be
affected in CRPS [31]. Therefore, based on our observation
of characteristic ANNA and PCA reactivity in some patients,
our results suggest that autoimmunity against the peripheral
nerve system could be of relevance in CRPS in a limited
subset of cases. Since the majority of CRPS patients did not
display antineuronal antibodies, a causal relationship remains
to be determined. Alternatively, in the subset of patients
with antineuronal antibodies, their expression might have
been a secondary event as a result of nerve damage [32]. It
would therefore be interesting to search for signs of actual
nerve damage in patients who display these antineuronal
antibodies and to search for the actual antigenic specificity
of the antibodies. To define whether or not antineuronal
antibodies could be causative forCRPS is of clinical relevance,
as immune therapies, such as corticosteroids and intravenous
immunoglobulin, have been shown to positively affect the
neurological outcome when a disorder is caused by an
antineuronal antibody directed against a cell surface antigen
[22]. Interestingly, a previous work has already shown that
someCRPS patients do respond to intravenous immunoglob-
ulin treatment [18].
Before speaking of clear evidence of an autoimmune etiol-
ogy, Witebsky’s criteria for an autoimmune disease should be
considered [33]. These criteria include (1) demonstration of
a specific antigen, (2) circumstantial evidence of an autoim-
mune or inflammatory disorder from clinical clues, and
(3) reproduction of clinical features in recipient animals by
passive transfer of putatively pathogenic antibodies.We argue
that CRPS definitely meets the second criterion. There are
indications that the first criterion is met as well; however, this
applies only to some of the CRPS patients. Andmore research
is needed to define specific antigens involved. Injection of
serum-IgG from a CRPS patient into groups of mice showed
abnormal physical behavior and a significant reduction in
rearing [34]. However, these findings are not a reproduction
of the clinical features, as needed for the third criterion.
Therefore, although suggestive, it remains uncertain whether
CRPS can be defined as an autoimmune disease.
In conclusion, our findings indicate an autoimmune-
related pathophysiology of CRPS in at least a subgroup of
CRPS patients. Further research is needed into defining this
subset and into the role of antibodies in the pathogenesis of
CRPS in these patients.
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